Quarterly report pursuant to Section 13 or 15(d)

Segments (Tables)

v3.4.0.3
Segments (Tables)
3 Months Ended
Mar. 31, 2016
Segment Reporting [Abstract]  
Operations and Assets for Operating Segments and Geographic Information
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the three months ended March 31,
(In thousands)
2016
 
2015
Revenue from services:
 
 
 
Pharmaceutical
$

 
$

Diagnostics
252,522

 
2,009

Corporate

 
60

 
$
252,522

 
$
2,069

Product revenues:
 
 
 
Pharmaceutical
$
19,899

 
$
15,486

Diagnostics

 

Corporate

 

 
$
19,899

 
$
15,486

Revenue from transfer of intellectual property:
 
 
 
Pharmaceutical
$
18,616

 
$
12,529

Diagnostics

 

Corporate

 

 
$
18,616

 
$
12,529

Operating (loss) income:
 
 
 
Pharmaceutical
$
(1,330
)
 
$
(37,924
)
Diagnostics
(2,355
)
 
(8,477
)
Corporate
(23,833
)
 
(9,979
)
Less: Operating loss attributable to noncontrolling interests

 
(534
)
 
$
(27,518
)
 
$
(56,914
)
Depreciation and amortization:
 
 
 
Pharmaceutical
$
2,861

 
$
1,756

Diagnostics
19,320

 
1,747

Corporate
18

 
22

 
$
22,199

 
$
3,525

Net loss from investment in investees:
 
 
 
Pharmaceutical
$
(2,050
)
 
$
(1,761
)
Diagnostics
(295
)
 

Corporate

 

 
$
(2,345
)
 
$
(1,761
)
Revenues:
 
 
 
United States
$
252,438

 
$
2,493

Ireland
22,144

 
12,104

Chile
6,983

 
6,452

Spain
4,023

 
3,937

Israel
4,743

 
4,213

Mexico
706

 
885

 
$
291,037

 
$
30,084


(In thousands)
March 31,
2016
 
December 31,
2015
Assets:
 
 
 
Pharmaceutical
$
1,246,467

 
$
1,234,752

Diagnostics
1,435,297

 
1,421,034

Corporate
111,442

 
143,402

 
$
2,793,206

 
$
2,799,188

Goodwill:

 

Pharmaceutical
$
255,159

 
$
251,225

Diagnostics
491,802

 
492,123

Corporate

 

 
$
746,961

 
$
743,348